Disease Development and Outcomes

Mary Alison Mahieu*, Dafna Gladman, Rosalind Ramsey-Goldman

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a disease of variable course and prognosis. Clinical manifestations of SLE are reviewed in this chapter, with an emphasis on the most common types of disease damage related to SLE itself and other factors. Tools to assess lupus outcomes, including disease activity, disease damage, and patient-reported outcomes, are increasingly used in clinical practice and clinical trials to improve care. Diagnostic and therapeutic advances have led to improved survival in SLE patients over the last 50. years, but lupus patients still have a higher mortality than the general population. Risk factors for mortality, including organ-specific SLE manifestations, race/ethnicity, and socioeconomic status, are discussed. A growing body of treatment guidelines and quality indicators provide a clinical framework to mitigate disease activity and damage and improve patient outcomes.

Original languageEnglish (US)
Title of host publicationSystemic Lupus Erythematosus
Subtitle of host publicationBasic, Applied and Clinical Aspects
PublisherElsevier Inc.
Pages31-37
Number of pages7
ISBN (Electronic)9780128020098
ISBN (Print)9780128019177
DOIs
StatePublished - Jan 1 2016

Fingerprint

Systemic Lupus Erythematosus
Mortality
Social Class
Clinical Trials
Guidelines
Survival
Therapeutics
Population

Keywords

  • Causes of death
  • Clinical manifestations
  • Disease activity
  • Disease damage
  • Mortality
  • Patient-reported outcomes
  • Quality indicators
  • Treatment guidelines

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Mahieu, M. A., Gladman, D., & Ramsey-Goldman, R. (2016). Disease Development and Outcomes. In Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects (pp. 31-37). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801917-7.00005-X
Mahieu, Mary Alison ; Gladman, Dafna ; Ramsey-Goldman, Rosalind. / Disease Development and Outcomes. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Inc., 2016. pp. 31-37
@inbook{947a841006a446678dbd1235244ec6e3,
title = "Disease Development and Outcomes",
abstract = "Systemic lupus erythematosus (SLE) is a disease of variable course and prognosis. Clinical manifestations of SLE are reviewed in this chapter, with an emphasis on the most common types of disease damage related to SLE itself and other factors. Tools to assess lupus outcomes, including disease activity, disease damage, and patient-reported outcomes, are increasingly used in clinical practice and clinical trials to improve care. Diagnostic and therapeutic advances have led to improved survival in SLE patients over the last 50. years, but lupus patients still have a higher mortality than the general population. Risk factors for mortality, including organ-specific SLE manifestations, race/ethnicity, and socioeconomic status, are discussed. A growing body of treatment guidelines and quality indicators provide a clinical framework to mitigate disease activity and damage and improve patient outcomes.",
keywords = "Causes of death, Clinical manifestations, Disease activity, Disease damage, Mortality, Patient-reported outcomes, Quality indicators, Treatment guidelines",
author = "Mahieu, {Mary Alison} and Dafna Gladman and Rosalind Ramsey-Goldman",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-801917-7.00005-X",
language = "English (US)",
isbn = "9780128019177",
pages = "31--37",
booktitle = "Systemic Lupus Erythematosus",
publisher = "Elsevier Inc.",
address = "United States",

}

Mahieu, MA, Gladman, D & Ramsey-Goldman, R 2016, Disease Development and Outcomes. in Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Inc., pp. 31-37. https://doi.org/10.1016/B978-0-12-801917-7.00005-X

Disease Development and Outcomes. / Mahieu, Mary Alison; Gladman, Dafna; Ramsey-Goldman, Rosalind.

Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Inc., 2016. p. 31-37.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Disease Development and Outcomes

AU - Mahieu, Mary Alison

AU - Gladman, Dafna

AU - Ramsey-Goldman, Rosalind

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Systemic lupus erythematosus (SLE) is a disease of variable course and prognosis. Clinical manifestations of SLE are reviewed in this chapter, with an emphasis on the most common types of disease damage related to SLE itself and other factors. Tools to assess lupus outcomes, including disease activity, disease damage, and patient-reported outcomes, are increasingly used in clinical practice and clinical trials to improve care. Diagnostic and therapeutic advances have led to improved survival in SLE patients over the last 50. years, but lupus patients still have a higher mortality than the general population. Risk factors for mortality, including organ-specific SLE manifestations, race/ethnicity, and socioeconomic status, are discussed. A growing body of treatment guidelines and quality indicators provide a clinical framework to mitigate disease activity and damage and improve patient outcomes.

AB - Systemic lupus erythematosus (SLE) is a disease of variable course and prognosis. Clinical manifestations of SLE are reviewed in this chapter, with an emphasis on the most common types of disease damage related to SLE itself and other factors. Tools to assess lupus outcomes, including disease activity, disease damage, and patient-reported outcomes, are increasingly used in clinical practice and clinical trials to improve care. Diagnostic and therapeutic advances have led to improved survival in SLE patients over the last 50. years, but lupus patients still have a higher mortality than the general population. Risk factors for mortality, including organ-specific SLE manifestations, race/ethnicity, and socioeconomic status, are discussed. A growing body of treatment guidelines and quality indicators provide a clinical framework to mitigate disease activity and damage and improve patient outcomes.

KW - Causes of death

KW - Clinical manifestations

KW - Disease activity

KW - Disease damage

KW - Mortality

KW - Patient-reported outcomes

KW - Quality indicators

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=84966990607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966990607&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801917-7.00005-X

DO - 10.1016/B978-0-12-801917-7.00005-X

M3 - Chapter

SN - 9780128019177

SP - 31

EP - 37

BT - Systemic Lupus Erythematosus

PB - Elsevier Inc.

ER -

Mahieu MA, Gladman D, Ramsey-Goldman R. Disease Development and Outcomes. In Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Inc. 2016. p. 31-37 https://doi.org/10.1016/B978-0-12-801917-7.00005-X